Interaktion autoaggressiver T- und B-Zellen beim Pemphigoid und Pemphigus

• Antragsteller: Professor Dr. Michael Hertl; Professor Dr. Nicolas Hunzelmann
• Fachliche Zuordnung: Dermatologie
• Förderung: Förderung von 2006 bis 2010
• Projektkennung: Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 23568688

• Erstellungsjahr: 2010

Zusammenfassung der Projektergebnisse

Keine Zusammenfassung vorhanden

Projektbezogene Publikationen (Auswahl)

• Anti-basement membrane zone antibodies in elderly patients with pruritic disorders and diabetes mellitus. Eur J Dermatol. 18:534-8,2008
  Jedlickova H, Racovska J, Niedermeier A, Feit J, Hertl M
  
• Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clin Immunol. 128:415-26, 2008
  Di Zenzo G, Thoma-Uszynski S, Fontao L, Calabresi V, Hofmann SC, Hellmark T, Sebbag N, Pedicelli C, Sera F, Lacour JP, Wieslander J, Bruckner-Tuderman L, Borradori L, Zambruno G, Hertl M
  
• Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol. 128:2850-8, 2008
  Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Hertl M
  
• Autoantibodies against desmocollins in European patients with pemphigus. Clin Exp Dermatol. 34:898-903, 2009
  Müller R, Heber B, Hashimoto T, Messer G, Müllegger R, Niedermeier A, Hertl M
  
• Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3,Clin Immunol. 2009 Dec 14
  Nagel A, Lang A, Engel D, Podstawa E, Hunzelmann N. de Pita O, Borradori L, Uter W, Herti M
  
• Clinical and immunological followup of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab. Dermatology 218:237-45, 2009
  Pfütze M, Eming R, Kneisel A, Kuhlmann U; Hoyer J, Hertl M
  
• IgG autoantibody reactivity against BPI80 and BP230 in elderly patients with pruritic dermatoses.Sr J Dermatol. 161:306-12, 2009
  Feliciani C, Caldarola G, Kneisel A, Podstawa E, Pfütze M, Pfützner W, Hertl M
  
• Pemphigus herpetiformis: analysis of the autoantibody profile during the disease course with changes in the clinical phenotype. Clin Exp Dermatol. 2009 Oct 23
  Lebeau S, Müller R, Masouye I, Hertl M, Borradori L
  
• Research in practice: Treatment of autoimmune bullous disorders. J Dtsch Dermatol Ges. 7:500-5, 2009
  Hertl M
  
• Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. J Invest Dermatol. 129:2202-10, 2009
  Nagel A, Podstawa E, Eickmann M, Müller HH, Hertl M. Eming R
  
• T and B cells target identical regions of the non-collagenous domain 1 of type VII collagen in epidermolysis bullosa acquisita.Clin Immunol. 2010 Jan 19
  Müller R, Dahler C, Möbs C, Wenzel E, Eming R, Messer G, Niedermeier A, Hertl M